Evidence map›Paper›PMID 38304309›Full record

ArticleFrontiers in medicine2023

Expert opinions and clinical experiences with chlormethine gel as maintenance treatment for patients with mycosis fungoides.

Larisa Geskin, Christiane Querfeld, Emmilia Hodak, Neda Nikbakht, Evangelia Papadavid, Marco Ardigò, Ulrike Wehkamp, Martine Bagot

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 6 countries.

Larisa GeskinColumbia University Medical Center, Columbia University, New York, NY, United States.
Christiane QuerfeldDivision of Dermatology and Department of Pathology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, United States.
Emmilia HodakDavidoff Medical Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
Neda NikbakhtDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, United States.
Evangelia PapadavidNational Center of Excellence for Rare Disease, Second Department of Dermatology and Venereology, Attikon University General Hospital, Athens, Greece.
Marco ArdigòSan Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Ulrike WehkampDepartment of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
Martine BagotDepartment of Dermatology, AP-HP, Université de Paris, Hôpital Saint-Louis, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRCity Of Hope National Medical Center · USColumbia University Irving Medical Center · USRabin Medical Center · ILSan Gallicano Hospital · ITThomas Jefferson University · USUniversity General Hospital Attikon · GRUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maintenance treatment can be recommended for patients with mycosis fungoides (MF) whose disease responds to primary treatment. While positive outcomes have been observed in small studies with maintenance therapy, there is a lack of practical guidelines and agreement on when and how maintenance therapy for MF should be approached. In this article, we discuss expert opinions and clinical experiences on the topic of maintenance therapy for patients with MF, with a focus on chlormethine gel. Ideally, patients should have a durable response before initiating maintenance therapy. The definition of and required duration of durable response are topics that are open to debate and currently have no consensus. Chlormethine gel has several attributes that make it suitable for maintenance therapy; it can be easily applied at home, can be combined with other treatment options for maintenance, and has a manageable safety profile. Chlormethine gel as maintenance therapy can be applied at decreasing frequencies after active treatment with chlormethine gel or other therapies until the minimally effective dose is reached. Patients generally tend to adhere well to chlormethine gel maintenance regimens and may remain on treatment for several years. The experiences described here may be useful for clinicians when deciding on maintenance treatment regimens for their patients. Development of guidelines based on clinical trial outcomes will be important to ensure the most effective maintenance treatment strategies are used for patients with MF.

Indexed as

chlormethine gelclinical experiencesexpert opinionsmaintenance therapymycosis fungoides

Identifiers

PMID38304309
PMCPMC10832661
OpenAlexW4390973231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.